Defining a pulmonary exacerbation in cystic fibrosis

Journal of Pediatrics

Volumn 139, Issue 3, 2001, Pages 359-365

  Rosenfeld, Margaret ^a,b,c,d,e   Emerson, Julia ^a,b,c,d,e   Williams Warren, Judy ^a,b,c,d,e   Pepe, Margaret ^a,b,c,d,e   Smith, Arnold ^a,b,c,d,e   Montgomery, A Bruce ^a,b,c,d,e   Ramsey, Bonnie ^a,b,c,d,e  

^a SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

^d UNIVERSITY OF MISSOURI   (United States)

^e NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; PILOCARPINE; PLACEBO; TOBRAMYCIN;

ADOLESCENT; ADULT; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL INFECTION; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SCORING SYSTEM; SWEAT TEST; SYMPTOMATOLOGY; TREATMENT OUTCOME;

EID: 0034821607     PISSN: 00223476     EISSN: None     Source Type: Journal    
DOI: 10.1067/mpd.2001.117288     Document Type: Article

References (23)

1. Management of pulmonary disease in patients with cystic fibrosis
2. What is a "pulmonary exacerbation" in cystic fibrosis?
3. Management of acute pulmonary exacerbations in cystic fibrosis: A critical appraisal
4. Outcome measures for clinical trials in CF: Summary of a Cystic Fibrosis Conference
5. Effect of high-dose ibuprofen in patients with CF
6. Efficacy and safety of chronic intermittent administration of inhaled tobramycin in patients with cystic fibrosis
7. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis
8. Serial changes in pulmonary functions in children hospitalized with cystic fibrosis
9. Evolution of pulmonary function during an acute exacerbation in hospitalized patients with cystic fibrosis
10. Ceftazidime in treatment of acute pulmonary exacerbations in patients with cystic fibrosis
11. Sputum changes associated with therapy for endobronchial exacerbation in cystic fibrosis
12. Ceftazidime therapy in patients with cystic fibrosis and multiple-drug-resistant Pseudomonas
13. Is antiPseudomonas therapy warranted in acute respiratory exacerbations in children with cystic fibrosis?
14. Alternative antibiotics for the treatment of Pseudomonas infections in cystic fibrosis
15. Modification of some markers of inflammation during treatment for acute respiratory exacerbation in cystic fibrosis
16. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for Pseudomonas exacerbations in cystic fibrosis
17. Relationship between clinical conditions, radiographic findings and pulmonary functions in patients with cystic fibrosis
18. Intravenous immune globulin treatment of pulmonary exacerbations in cystic fibrosis
19. Clinical and bacteriological responses to three antibiotic regimens for acute exacerbations of cystic fibrosis: Ticarcillin-tobramycin, azlocillin-tobramycin, and azlocillin-placebo
20. The chest roentgenogram in cystic fibrosis: A new scoring system
21. A new prognostic score and clinical evaluation system for cystic fibrosis
22. Long-term study of one hundred five patients with cystic fibrosis: Studies made over a five- to fourteen-year period